BioLife Solutions (BLFS) Stock Price, News & Analysis

Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Key Stats

• Today's Range: $25.20 to $25.81
• 50-Day Range: $20.64 to $25.91
• 52-Week Range: $19.10 to $29.55
• Volume: 353,804 shs
• Average Volume: 483,485 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.29
• Consensus Rating: Buy

BioLife Solutions Stock Analysis - MarketRank™

BioLife Solutions scored higher than 52% of companies evaluated by MarketBeat, and ranked 532nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

BioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioLife Solutions has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioLife Solutions are expected to grow in the coming year, from ($0.30) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLife Solutions is -211.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLife Solutions is -211.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLife Solutions has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.45% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLife Solutions does not currently pay a dividend.

Dividend Growth

BioLife Solutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.45% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.41

News Sentiment

BioLife Solutions has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for BioLife Solutions this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for BLFS on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,499,658.00 in company stock.

Percentage Held by Insiders

Only 2.20% of the stock of BioLife Solutions is held by insiders.

Percentage Held by Institutions

93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BLFS Stock Analysis - Frequently Asked Questions

How have BLFS shares performed this year?

BioLife Solutions' stock was trading at $25.96 at the beginning of the year. Since then, BLFS stock has decreased by 2.0% and is now trading at $25.43.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its earnings results on Thursday, August, 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.31. The medical equipment provider had revenue of $25.42 million for the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive trailing twelve-month return on equity of 0.16%.
Read the conference call transcript.

Who are BioLife Solutions' major shareholders?

BioLife Solutions' top institutional investors include Invesco Ltd. (7.48%), Ameriprise Financial Inc. (2.26%), Geode Capital Management LLC (1.93%) and Palisade Capital Management LP (1.92%). Insiders that own company stock include Casdin Partners Master Fund, L, Greef Roderick De, Aby J Mathew, Michael Rice, Karen A Foster, Troy Wichterman, Todd Berard, Garrie Richardson, Sarah Aebersold, Geraint Phillips, Marcus Schulz, Amy Duross and Sean Werner.
View institutional ownership trends.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/27/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BLFS
• CIK: 834365
• Web: www.biolifesolutions.com
• Phone: (425) 402-1400
• Fax: 425-402-1433
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioLife Solutions: $31.29
• High Price Target: $33.00
• Low Price Target: $30.00
• Potential Upside/Downside: +23.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.18 million
• Net Margins: -5.39%
• Pretax Margin: -18.34%
• Return on Equity: 0.16%
• Return on Assets: 0.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.43
• Quick Ratio: 3.45

Sales & Book Value

• Annual Sales: $93.47 million
• Price / Sales: 12.97
• Cash Flow: $0.12 per share
• Price / Cash Flow: 209.37
• Book Value: $7.25 per share
• Price / Book: 3.49

Miscellaneous

• Outstanding Shares: 47,905,000
• Free Float: 46,851,000
• Market Cap: $1.21 billion
• Optionable: Optionable
• Beta: 1.76